Montelukast sodium hydrate
SIGMA/SML0101 - ≥98% (HPLC)
Synonym: 1-
Empirical Formula (Hill Notation): C35H35ClNO3S·Na · xH2O
Molecular Weight: 608.17 (anhydrous basis)
MDL Number: MFCD20527317
Linear Formula: C35H35ClNO3S·Na · xH2O
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to tan |
form | powder |
InChI | 1S/C35H36ClNO3S.Na.H2O/c1 |
InChI key | QAXHQHBRRJHZHL-ZPQUALOVSA |
optical activity | [α]/D +90 to +106° in methanol (c=1) |
originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
Quality Level | 100 |
SMILES string | O.[Na+].CC(C)(O)c1ccccc1C |
solubility | DMSO: ≥8 mg/mL at 60 °C |
storage condition | desiccated |
storage temp. | 2-8°C |
Application: | Montelukast sodium hydrate has been used as a positive control drug to study the protective effects of Gumiganghwal-tang aqueous extract (GGTA) against airway inflammation and pulmonary fibrosis. |
Biochem/physiol Actions: | Montelukast sodium hydrate is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is a subtype specific CysLT1 receptor antagonist. |
Features and Benefits: | This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
Features and Benefits: | This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: | 10, 50 mg in glass bottle |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352200 |